Table of Contents

P-Selectin-Mediated Monocyte–Cerebral Endothelium Adhesive Interactions Link Peripheral Organ Inflammation To Sickness Behaviors

  1. Mark G. Swain1
  1. 1Immunology Research Group and
  2. 2Gastrointestinal Research Group, Calvin, Phoebe, and Joan Snyder Institute for Chronic Diseases, and
  3. 3Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1
  1. Author contributions: C.D., K.R., K.M.S., D.M.M., Q.J.P., and M.G.S. designed research; C.D., K.R., T.L., K.M.S., and A.W. performed research; C.D. and K.R. analyzed data; C.D., D.M.M., Q.J.P., and M.G.S. wrote the paper.

Abstract

Sickness behaviors, such as fatigue, mood alterations, and cognitive dysfunction, which result from changes in central neurotransmission, are prevalent in systemic inflammatory diseases and greatly impact patient quality of life. Although, microglia (resident cerebral immune cells) and cytokines (e.g., TNFα) are associated with changes in central neurotransmission, the link between peripheral organ inflammation, circulating cytokine signaling, and microglial activation remains poorly understood. Here we demonstrate, using cerebral intravital microscopy, that in response to liver inflammation, there is increased monocyte specific rolling and adhesion along cerebral endothelial cells (CECs). Peripheral TNFα-TNFR1 signaling and the adhesion molecule P-selectin are central mediators of these monocyte–CEC adhesive interactions which were found to be closely associated with microglial activation, decreased central neural excitability and sickness behavior development. Similar monocyte-CEC adhesive interactions were also observed in another mouse model of peripheral organ inflammation (i.e., 2,4-dinitrobenzene sulfonic acid-induced colitis). Our observations provide a clear link between peripheral organ inflammation and cerebral changes that impact behavior, which can potentially allow for novel therapeutic interventions in patients with systemic inflammatory diseases.

  • Received March 28, 2013.
  • Revision received July 12, 2013.
  • Accepted August 12, 2013.